SMi presents its 11th annual Advances and Progress in Drug Design event...

The number of pharmaceutical products entering the market has declined in the last decade. With the economic downturn and increasing threat from generic companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs. Many pharmaceutical and biotechnology companies are now searching for effective strategies to improve hit-to-lead conversion and to identify unsuccessful compounds early in the development process.

SMi’s Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design. 

Here is what last year's delegates had to say... "Excellent quality of speeches and an intimate environment" Thomson Reuters "Highly specialised, useful information" Sanofi-aventis

Why should you attend this event?

Why you should attend this conference

• Understand key strategies to increase the clinical success of your product
• Evaluate the design of allosteric modulators for the treatment of CNS disorders
• Discuss protein-protein interactions
• Identify novel targets in drug discovery
• Hear the latest in rational drug design
• Understand how computational tools can be used to reduce drug toxicity
• Use this as a platform to further your understanding of this field 
 

Who attended in 2011? Companies included... 

Abbott Laboratories ArtusLabs Astellas Pharma Inc AstraZeneca Bayer Healthcare Boehringer Ingelheim Pharmaceuticals Chemical Computing Group Cresset Group Eli Lilly Genentech GlaxoSmithKline Grunenthal Gmbh

Key Organics Limited Lifechemicals Lilly S.A. MedImmune Inc. Merck KGAA Merck Serono SA                                  OpenEye Scientific Software Sanofi-Aventis Schrodinger Selcia Ltd Shionogi & Co., Ltd Simulations Plus, Inc.

Our expert speaker line-up also includes:

Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
Mike Hann, Director of Structural Biology Europe, GSK
Herbert Nar, Director Structural Research, Boehringer Ingelheim
John Mathias, Head of the Pfizer HTS CoE, Head of Medicinal Chemistry - Inflammation & Remodelling
Pfizer
José Duca, Head of CADD, Novartis Institutes for BioMedical Research, Inc.
Gregor Macdonald, Head of Neuroscience Chemistry, Janssen Pharmaceuticals, Johnson & Johnson PRD
Matthias Frech, Head of Molecular Interaction & Biophysics, Merck
Jonathan Mason, Head of Computational Chemistry & Chief Scientist, Heptares Therapeutics & Lundbeck
Kenton Longenecker, Senior Scientist, Structure-based Drug Design, Protein X-ray Crystallography, Abbott Laboratories
Richard Friesner, Proffessor and Schrödinger co-founder,  Columbia University
Morten Dahl Sørensen, Head of Computational Chemistry, LEO Pharma

Who should attend?

Who should attend this conference?

VPs, Directors, Heads, Senior Managers, Principal Scientists in Pharmaceutical, Biotech, Academics from:

• Outsourcing • Structure and Informatics • Computer-aided Drug Design • Computational Chemistry • Cancer Research • Cancer Pharmacology • Medicinal Chemistry • Pharmacology • Molecular Imaging

• Drug Discovery & Design • Target Discovery • Molecular Discovery • Drug Development • Target Discovery • Translational Sciences • Biophysics • Clinical Development • Structural Biology